Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | RAD52 | P43351 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | MMP12 | P39900 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL362000 | 0.87 | POLB (0.50) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL4429286 | 0.81 | PRKCI (0.52) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL27786200 | 0.81 | PRKCI (0.52) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL571364 | 0.81 | PRKCI (0.52) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL29724218 | 0.81 | PRKCI (0.52) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL1266025 | 0.81 | PRKCI (0.52) | PRKCIKDM4EMAPTRAD52CYP3A4 | |
| Hydrochloric Acid SCHEMBL11090118 | 0.80 | KDM4E (0.53) | POLBCASP6CTDSP1PRKCIKDM4E | |
| Potassium SCHEMBL2918771 | 0.80 | PRKCI (0.50) | POLBCASP6CTDSP1PRKCIKDM4E | |
| SCHEMBL7174501 | 0.80 | PARP1 (0.61) | CA12CA9SMN1; SMN2 | |
| SCHEMBL11783649 | 0.79 | MMP12 (0.49) | PRKCIKDM4EMAPTRAD52CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980365-B | Benzimidazol-2-amines as mIDH1 inhibitors | 拜耳医药股份公司 | 2019-06-21 | — | — | CN | claimed |
| EP-3407877-A1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | Galderma Research & Development (FR) | 2018-12-05 | — | — | EP | claimed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | claimed |
| CN-107295799-A | Parg inhibiting compounds | 癌症研究科技有限公司 | 2017-10-24 | — | — | CN | claimed |
| WO-2017129897-A1 | NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-08-03 | — | — | WO | claimed |
| EP-3105210-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-12-21 | — | — | EP | claimed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | claimed |
| WO-2015121209-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-20 | — | — | WO | claimed |
| EP-2744805-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | Amgen Inc. (US) | 2014-06-25 | — | — | EP | claimed |
| WO-2013025883-A1 | HETEROARYL SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2013-02-21 | — | — | WO | claimed |
| EP-2523559-A1 | COMPOUNDS AND METHODS | GlaxoSmithKline LLC (US) | 2012-11-21 | — | — | EP | claimed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2009007390-A2 | 2-PYRAZ INYLBENZ IMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | claimed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | claimed |
| EP-1879877-A2 | ANTIMICROBIAL AGENTS | Ranbaxy Laboratories Limited (IN) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117762-A2 | ANTIMICROBIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-09 | — | — | WO | claimed |
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250228824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF ITO AS TREATMENT FOR THE J WAVE SYNDROMES AND HYPOTHERMIA | SIMON FRASER UNIVERSITY (CA) | 2025-07-17 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365681-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | POLB 2355/4885CASP6 3660/4885CTDSP1 2015/4885 |
| US-20250228824-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF ITO AS TREATMENT FOR THE J WAVE SYNDROMES AND HYPOTHERMIA | KCNH2, KCNJ1, KCNJ8 | POLB 3887/4885CASP6 2006/4885CTDSP1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.